Skip to main content
Year archive

STARPHARMA HOLDINGS LIMITED — 2019 filings

All 59 regulatory filings released by STARPHARMA HOLDINGS LIMITED (SPL) in 2019, sourced directly from the official regulator.

59 Filings
2019 Period
2019 filings (59)
Filing Released Lang
Commencement of phase 1 trial for AZD0466 utilising DEP 2 pages 60.5KB
Regulatory Filings
2019-12-29 English
Starpharma receives $4.9M R&D tax incentive refund 2 pages 53.0KB
Capital/Financing Update
2019-12-15 English
DEP cabazitaxel progresses to phase 2 on positive results 4 pages 299.8KB
Regulatory Filings
2019-12-09 English
Appendix 3B 9 pages 168.8KB
Share Issue/Capital Change
2019-12-03 English
Change in Director's Interest Notice - J Fairley 2 pages 157.8KB
Director's Dealing
2019-12-03 English
AGM - Chairman address and CEO presentation 40 pages 3.0MB
AGM Information
2019-11-20 English
AGM Results 2 pages 186.2KB
Declaration of Voting Results & Voting Rights Announcements
2019-11-20 English
VivaGel condom receives regulatory approval in Europe 2 pages 65.5KB
Regulatory Filings
2019-11-19 English
2019 AGM details 1 page 45.2KB
AGM Information
2019-11-18 English
UK launch of VivaGel BV 2 pages 76.7KB
Regulatory Filings
2019-11-12 English
Becoming a substantial holder - SPL 7 pages 602.6KB
Regulatory Filings
2019-11-11 English
DEP outperforms Gemzar in human pancreatic cancer model 4 pages 107.6KB
Regulatory Filings
2019-10-30 English
Quarterly Cashflow Report 6 pages 181.9KB
Interim / Quarterly Report
2019-10-29 English
Change in substantial holding 8 pages 103.2KB
Major Shareholding Notification
2019-10-22 English
Ceasing to be a substantial holder 4 pages 43.8KB
Major Shareholding Notification
2019-10-22 English
Notice of Annual General Meeting/Proxy Form 14 pages 1.7MB
AGM Information
2019-10-17 English
Appendix 3B 9 pages 168.6KB
Capital/Financing Update
2019-10-16 English
Starpharma to present at US Drug Delivery Conference 2 pages 60.3KB
Investor Presentation
2019-10-07 English
Appendix 3B 8 pages 164.6KB
Share Issue/Capital Change
2019-09-30 English
Change in Director's Interest Notice - J Fairley 2 pages 81.3KB
Director's Dealing
2019-09-30 English
FDA Authorises Clinical Trial with AstraZeneca DEP product 2 pages 68.4KB
Regulatory Filings
2019-09-25 English
AGM Date Notification 1 page 44.5KB
AGM Information
2019-09-23 English
DEP irinotecan synergistic with Lynparza in refractory model 4 pages 121.8KB
Regulatory Filings
2019-09-11 English
Change in substantial holding 5 pages 161.4KB
Major Shareholding Notification
2019-09-08 English
VivaGel BV regulatory approvals continue in Asia 2 pages 131.7KB
Regulatory Filings
2019-09-02 English
Positive results with Targeted DEP using antibody fragment 3 pages 103.5KB
Regulatory Filings
2019-08-28 English
Promising efficacy signals observed in ongoing DEP trials 3 pages 241.3KB
Regulatory Filings
2019-08-27 English
Starpharma annual report and full year financial results 94 pages 4.6MB
Annual Report
2019-08-27 English
Appendix 4G - Corporate Governance Statement 9 pages 131.4KB
Governance Information
2019-08-27 English
First Asian Regulatory Approvals Received for VivaGel BV 2 pages 65.4KB
Regulatory Filings
2019-08-14 English
Starpharma commences phase 1/2 DEP irinotecan trial 3 pages 137.6KB
Regulatory Filings
2019-08-07 English
Appendix 3B 8 pages 172.0KB
Capital/Financing Update
2019-07-28 English
Quarterly Cashflow Report 6 pages 217.1KB
Interim / Quarterly Report
2019-07-15 English
Shareholder Update July 2019 4 pages 630.9KB
Management Reports
2019-06-30 English
VivaGel BV launched in Europe 3 pages 73.5KB
Regulatory Filings
2019-06-26 English
Starpharma presents at Macquarie Emerging Leaders Forum 1
Investor Presentation
2019-06-19 English
US patent granted for DEP Bcl2/xL inhibitor conjugates 2 pages 64.9KB
Regulatory Filings
2019-06-11 English
Okamoto launches VivaGel condom in Japan 2 pages 118.1KB
Regulatory Filings
2019-06-03 English
Starpharma signs second oncology agreement with AstraZeneca 2 pages 130.0KB
Capital/Financing Update
2019-06-02 English
Starpharma presents at UBS Healthcare Conference 1
Investor Presentation
2019-05-28 English
DEP irinotecan combination outperforms in colon cancel model 4 pages 219.6KB
Regulatory Filings
2019-05-23 English
Regulatory progress for VivaGel BV in the US 2 pages 62.5KB
Regulatory Filings
2019-05-22 English
Starpharma to present at US Drug Delivery Conference 18 pages 1.8MB
Investor Presentation
2019-05-06 English
Ceasing to be a substantial holder 3 pages 191.4KB
Major Shareholding Notification
2019-04-30 English
Starpharma presents at Macquarie Australia Conference 1
Investor Presentation
2019-04-30 English
Quarterly Cashflow Report 6 pages 171.1KB
Interim / Quarterly Report
2019-04-28 English
First VivaGel BV launch globally in Australia by Aspen 2 pages 132.0KB
Regulatory Filings
2019-04-15 English
Starpharma meets with US FDA to discuss VivaGel BV 2 pages 116.0KB
Regulatory Filings
2019-04-10 English
Starpharma Investor Presentation to Goldman Sachs Conference 36 pages 3.1MB
Investor Presentation
2019-04-02 English
Appendix 3B 8 pages 176.2KB
Share Issue/Capital Change
2019-03-18 English
Shareholder Update March 2019 2 pages 468.6KB
Capital/Financing Update
2019-03-17 English
Starpharma receives $4.0M R&D tax incentive refund 1
Capital/Financing Update
2019-03-11 English
Interim Report and Half-Yearly Financial Results 22 pages 644.1KB
Interim / Quarterly Report
2019-02-26 English
Appendix 3B 8 pages 182.8KB
Share Issue/Capital Change
2019-02-07 English
Quarterly Cashflow Report 6 pages 245.3KB
Interim / Quarterly Report
2019-01-29 English
Shareholder Update January 2019 4 pages 571.3KB
Investor Presentation
2019-01-16 English
Becoming a substantial holder 3 pages 496.6KB
Major Shareholding Notification
2019-01-13 English
Response to ASX Aware Letter 8 pages 461.4KB
Regulatory Filings
2019-01-06 English
VivaGel condom receives final regulatory approval in Japan 2 pages 117.9KB
Capital/Financing Update
2019-01-01 English